With a new therapeutic product, researchers have managed to cure arthritis in mice for the first time. The scientists are now planning to test the efficacy of the drug in humans.
Rheumatoid arthritis is a condition that causes painful inflammation of several joints in the body. The joint capsule becomes swollen, and the disease can also destroy cartilage and bone as it progresses. Rheumatoid arthritis affects 0.5% to 1% of the world’s population. Up to this point, doctors have used various drugs to slow or stop the progression of the disease. But now, ETH Zurich researchers have developed a therapy that takes the treatment of rheumatoid arthritis in mice to a new level: after receiving the medication, researchers consider the animals to be fully cured.
The drug is a biotechnologically produced active substance consisting of two fused components. One component is the body’s own immune messenger interleukin 4 (IL-4); previous studies have shown that this messenger protects mice with rheumatoid arthritis against cartilage and bone damage. ETH scientists have coupled an antibody to IL-4 that, based on the key-lock principle, binds to a form of a protein that is found only in inflamed tissue in certain diseases (and in tumour tissue).
Localised drug delivery
“As a result of combination with the antibody, IL-4 reaches the site of the disease when the fusion molecule is injected into the body,” says pharmacist Teresa Hemmerle, who has just completed her dissertation in the group of Dario Neri, a professor at the Institute of Pharmaceutical Sciences. Together with Fabia Doll, also a PhD pharmacist at ETH, she is the lead author of the study. “It allows us to concentrate the active substance at the site of the disease. The concentration in the rest of the body is minimal, which reduces side-effects,” she says.
The Latest on: Curing arthritis
via Google News
The Latest on: Curing arthritis
- MorphoSys' licensee Janssen receives European approval for Tremfya to treat adults with active psoriatic arthritison December 4, 2020 at 3:00 am
MorphoSys' licensee Janssen receives European approval for Tremfya to treat adults with active psoriatic arthritis: Munich, Germany Friday, December 4, 2020, 16:30 Hrs [IST] Morph ...
- Monoclonal antibodies, President Trump's 'miracle cure' for COVID-19, have arrived in Peoriaon December 3, 2020 at 3:19 am
The medical world is not as effusive about the treatment as Trump, but there is hope that it will help reduce hospitalizations.
- Virtual Jingle Bell Run will boost support for people with arthritison November 30, 2020 at 6:35 pm
Although the Jingle Bell Run will be virtual, the Arthritis Foundation says the support is more important than ever. They are helping 75% more people with information and support.
- Rheumatoid arthritis: Thunder god vine is comparable to drug treatments, research suggestson November 30, 2020 at 2:40 pm
Rheumatoid arthritis is a long-term condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. According to the NHS, some people with ...
- Woman's Doctor: Knowing the symptoms of psoriatic arthritison November 28, 2020 at 6:19 am
S WOMAN'S DOCTOR, KNOWING THE SYMPTOMS OF PSORIATIC ARTHRITIS, IT'S A DOUBLE WHAMMY OF AUTOIMMUNE DISORDERS. NOT ONLY DO PSORIATIC ARTHRITIS SYMPTOMS MIMIC THOSE OF PSORIASIS, LIKE PATCHES OF RED, ...
- A matching gift to provide twice the arthritis research poweron November 26, 2020 at 9:59 am
An anonymous donor has stepped forward with an offer to match all donations to Arthritis Research Canada up to $10,000. The organization is North America's largest clinical arthritis research centre, ...
- Janssen's Tremfya approved for active psoriatic arthritison November 26, 2020 at 1:34 am
The European Commission has approved Janssen’s Tremfya (guselkumab) as a first-in-class treatment for active psoriatic arthritis (PsA). The decision allows doctors to prescribe the drug for adults ...
- European Commission Approves Janssen’s TREMFYA® (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)on November 24, 2020 at 11:01 pm
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved TREMFYA ® ▼ (guselkumab) for the treatment of adult patients with active ...
- CBD a ‘wonder cure’ is changing people’s liveson November 23, 2020 at 3:20 am
Can’t sleep? Anxious? Depressed? In pain? If you answered yes of any of these, chances are you’ve already heard of CBD, or cannabidiol. Derived directly from the hemp plant, CBD is one of hundreds of ...
- Fishing Updates; Sea cuke cures; Bambino'son November 22, 2020 at 4:00 pm
Fishing Updates; Sea cuke cures; Bambino's. By LAINE WELCH . November 23, 2020 Monday PM (SitNews) - Lots of fishing updates and wrap ups continue across Alaska from Ketchikan to ...
via Bing News